Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2021-06-23 Investor Presentation
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
PTX Completes CAR-T Manufacturing Milestone for OmniCAR 5 pages 400.8KB
Investor Presentation Classification · 95% confidence The document is a detailed announcement from Prescient Therapeutics about completing a manufacturing milestone for their next-generation CAR-T immunotherapy platform. It includes descriptions of the technology, research progress, and upcoming investor briefing details. There are no financial statements, regulatory certifications, or voting results. The content focuses on operational progress and investor communication rather than financial results or governance changes. It is not a full financial report, audit, or earnings release. The document is longer than 5,000 characters and contains substantive information about company progress and investor engagement, fitting the profile of an Investor Presentation rather than a brief announcement or regulatory filing. Therefore, the most appropriate classification is Investor Presentation (IP).
2021-06-23 English
Response to ASX Price Query 3 pages 416.4KB
Regulatory Filings Classification · 95% confidence The document is a letter from ASX Listings Compliance to Prescient Therapeutics Limited regarding a price query about recent trading activity in the company's securities. It includes a request for information about any undisclosed material information that might explain the price and volume changes, references to ASX Listing Rules (3.1, 3.1A, 17.1, 17.3), and instructions about trading halts and suspensions. The company responds confirming no undisclosed information and compliance with listing rules. This is a regulatory compliance correspondence related to market disclosure and trading activity, not a financial report, earnings release, or management discussion. It is a regulatory filing notifying the market and regulator about compliance with continuous disclosure obligations and responding to a price query. The document length (6852 characters) and content indicate it is not a report publication announcement or a full report but a regulatory communication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-06-02 English
Capital Structure Update - Expiry of Unlisted Options 3 pages 305.0KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 17 May 2021 from Prescient Therapeutics regarding the expiry of unlisted options and current securities on issue. It includes detailed information about the number and exercise prices of options and shares, but does not contain financial statements, earnings data, or management discussion of financial results. The document also provides background on the company's business and products, and includes forward-looking statements and disclaimers. There is no indication that this is a full financial report, audit report, earnings release, or regulatory filing. It is an update on capital structure related to options expiry and securities outstanding, which fits best under Capital/Financing Update (CAP). The document length (9302 characters) is sufficient to be more than a brief announcement, and it contains substantive information about securities, not just a notice or link to a report. Therefore, the classification is CAP with high confidence.
2021-05-16 English
PTX signs CAR-T agreement with Peter MacCallum 4 pages 315.1KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about a new research agreement between Prescient Therapeutics Limited and the Peter MacCallum Cancer Centre to develop next-generation CAR-T therapies. It includes descriptions of the research programs, scientific background, company strategy, and quotes from executives. There are no financial statements, quarterly or annual results, nor any regulatory or legal filings. The content is focused on a corporate partnership and research development update rather than financial performance or governance changes. It is not a report, transcript, or regulatory filing but rather a corporate announcement about a research collaboration and grant funding. This fits best under the category of a general Regulatory Filing (RNS) as it is a regulatory announcement that does not fit other specific categories like earnings release, capital update, or management information.
2021-05-09 English
March 2021 Quarterly Update and Appendix 4C 10 pages 166.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'March 2021 Quarterly Update and Appendix 4C' and contains detailed financial and operational results for the quarter ended 31 March 2021. It includes a cash flow statement and discusses quarterly financial performance, clinical progress, and management updates. The presence of the Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly financial report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-04-28 English
PTX-200 AML Trial Progresses to Higher Dose 3 pages 349.6KB
Regulatory Filings Classification · 90% confidence The document is a detailed announcement about the progress of a clinical trial (PTX-200 AML Trial) by Prescient Therapeutics Limited. It includes information about the trial phases, doses, patient responses, and company background. There are no financial statements, regulatory certifications, or voting results. The content focuses on clinical trial progress and company product development updates rather than financial performance or governance. It is not a full annual or interim report, nor is it a regulatory filing or earnings release. The document is a corporate announcement about clinical trial progress, which does not fit into the typical financial or governance filing categories. Given the nature of the content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2021-04-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.